Schemes are being urged to abstain from approving biopharmaceutical company Renovo's remuneration report because governance watchdogs believe targets could lead to executives taking "risky decisions".
Pensions Investment Research Consultants is concerned about a resolution to increase the maximum award available under the firm’s long-term incentive scheme and a series of “milestones” used to jud...
To continue reading this article...
Join Professional Pensions
Become a Professional Pensions Lite Member today
In just a few clicks you can start your free Professional Pensions Lite membership for 12 months, providing you access to:
- Three complimentary articles per month covering the latest real-time news, analysis and opinion from the industry
- Receive important and breaking news stories via our two daily news alerts
- Hear from industry experts and other forward-thinking leaders
